HomeNerviano Medical Sciences to present data on novel anticancer molecules at the AACR Annual Meeting 2013

Nerviano Medical Sciences to present data on novel anticancer molecules at the AACR Annual Meeting 2013

Nerviano, 06.03.2013

Nerviano Medical Sciences will disclose data on novel anticancer molecules at the AACR Annual Meeting 2013.

The presentations include:

Ardini, E et al: “Identification of a highly potent, selective and orally available RET inhibitor with antitumor efficacy in RET-dependent tumor models”. Abstract Number: 2091 Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Ardini, E et al: “The ALK inhibitor NMS-E628 also potently inhibits ROS1 and induces tumor regression in ROS-driven models”. Abstract Number: 2092 Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Colombo, R et al: “Targeting aneuploidy with NMS-P153, a tight binder inhibitor of the spindle assembly checkpoint MPS1 (TTK) kinase”. Abstract Number: 2097. Presentation Time: Monday, Apr 08, 2012, 1:00 PM - 5:00 PM

Montagnoli, A et al: “Novel isoquinolinone derivatives with dual PARP-1/PARP-3 inhibitory activity are highly active against pTEN mutated colorectal cancer and glioblastoma models”. Abstract Number: 3259. Presentation Time: Tuesday, Apr 09, 2012, 8:00 AM -12:00 PM

Further contributions achieved in collaborative work will be presented by partners (Abstract Number: 4634, “Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin’s lymphoma are effective in cell lines resistant to auristatin based ADCs”; Abstract Number: 4416 “A reporter mouse to measure drug myelotoxicity in time”).